Clin2Atlas
AtlasOther conditionsBlindness and vision loss

Glaucoma

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Metipranolol approved (FDA)1990 — Dapiprazole approved (FDA)1994 — Dorzolamide approved (FDA)1996 — Latanoprost approved (FDA)1996 — Brimonidine approved (FDA)1998 — Brinzolamide approved (FDA)2001 — Bimatoprost approved (FDA)2001 — Travoprost approved (FDA)2007 — Lisdexamfetamine approved (FDA)2012 — Tafluprost approved (FDA)2013 — Neostigmine approved (FDA)2017 — Latanoprostene bunod approved (FDA)2017 — Netarsudil approved (FDA)2022 — Omidenepag isopropyl approved (FDA)
1989: Drug approval — Metipranolol approved (FDA). 1990: Drug approval — Dapiprazole approved (FDA). 1994: Drug approval — Dorzolamide approved (FDA). 1996: Drug approval — Latanoprost approved (FDA). 1996: Drug approval — Brimonidine approved (FDA). 1998: Drug approval — Brinzolamide approved (FDA). 2001: Drug approval — Bimatoprost approved (FDA). 2001: Drug approval — Travoprost approved (FDA). 2007: Drug approval — Lisdexamfetamine approved (FDA). 2012: Drug approval — Tafluprost approved (FDA). 2013: Drug approval — Neostigmine approved (FDA). 2017: Drug approval — Latanoprostene bunod approved (FDA). 2017: Drug approval — Netarsudil approved (FDA). 2022: Drug approval — Omidenepag isopropyl approved (FDA)

What's being tested now

2000: 1 trials started2002: 1 trials started2006: 1 trials started2013: 1 trials started2014: 3 trials started2015: 1 trials started2016: 1 trials started2017: 2 trials started2018: 5 trials started2019: 7 trials started2020: 4 trials started2021: 7 trials started2022: 27 trials started2023: 25 trials started2024: 34 trials started2025: 84 trials started2026: 87 trials started200020102020202687

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 272 active Glaucoma trials on Clin2 →

Related

CataractAge-related macular degenerationRefraction disordersNear vision lossOther vision loss

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.